Abstract: An intermediate device 10A includes a transfer unit 11 that transfers a request including data to be transmitted from a local 30 to a remote 50, and a generation unit 12 that generates a pseudo-response to the request and returns the pseudo-response to the local 30. The intermediate device 10B includes a discard unit 13 that discards a response to the request from the remote 50. An intermediate device 20B includes a generation unit 22 that generates a pseudo-request based on an initial request for requesting data transmission from the local 30 to the remote 50 and transmits the pseudo-request to the remote 50, and a transfer unit 24 that transfers a response including data to be transmitted from the remote 50 to the local 30. The intermediate device 20A includes the discard unit 21 that discards a subsequent request from the local 30.

Abstract: An object of the present disclosure is to make it possible to measure an IP flow corresponding to time-varying, high-speed traffic. The present disclosure is a device that monitors traffic in a network, the device comprising a memory that records, for each flow in the network, metadata and flow information to be used in measurement, wherein a traffic state is forecasted using a packet flowing in the network; and a recording area for the metadata and the flow information in the memory is set based on the forecasted traffic state.

Abstract: The present invention relates to the development of a stomatological composition and a kit each comprising an NSAID such as ibuprofen, a heparin compound, or a pharmaceutically acceptable salt thereof for the prevention, alleviation, or treatment of inflammations associated with oral cavity diseases and/or pains/infections associated with the inflammations and of inflammatory pain diseases/infections of the pharynx and/or the esophagus, and to a method for producing the composition and a method of use of the composition for the production of a medicament.

Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.

Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.

Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.

Abstract: Aspects of the invention include organoleptically acceptable solid oral dosage compositions of ibuprofen. Solid oral dosage compositions according to certain embodiments include ibuprofen and a methacrylic acid copolymer in an amount sufficient to make the composition organoleptically acceptable for administering in an oral cavity of a subject to deliver ibuprofen to the subject. Methods for preparing and using solid oral dosage compositions of the invention are also described.

Abstract: Local anesthetic emulsion compositions are provided. The local anesthetic emulsion compositions may include: an oily phase comprising a eutectic mixture of a local anesthetic and an acyclic amide; a surfactant; and an aqueous phase. Also provided are methods of making and using the emulsions.

Abstract: Local anesthetic emulsion compositions are provided. The local anesthetic emulsion compositions may include: an oily phase comprising a eutectic mixture of a local anesthetic and an acyclic amide; a surfactant; and an aqueous phase. Also provided are methods of making and using the emulsions.

Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.

Abstract: The present invention provides for methods of administering by a pulmonary route a bisphosphonate active agent in combination with a pyrazolone derivative to a subject. Also provided are pharmaceutical compositions for use in practicing methods according to embodiments of the invention. The methods and compositions according to embodiments of the invention find use in a variety of different applications, including but not limited to, the treatment of bone absorption disease conditions.

Abstract: Methods and compositions of treating a subject for post-surgical pain are provided. In the subject methods, a subject is treated for post-surgical pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl emulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and an surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.

Abstract: Organoleptically acceptable oral dosage formulations of an indole receptor serotonin agonist, and methods of making and using the same, are provided. An aspect of the formulations is that they include an indole receptor serotonin agonist and a masking component. In certain embodiments, the masking component includes one or more of an amino acid and an organic acid. The subject invention finds use in a variety of applications.

Abstract: The present invention provides for methods of administering by a pulmonary route an effective amount of a bisphosphonate active agent to a subject. Aspects of the invention including administering the active agent to the subject in conjunction with one or more mucosal membrane protecting agents, where the protecting agent may include one or more of a protecting enzyme and/or a protecting amino acid and/or a protecting peptide. Also provided are inhalant compositions for use in practicing methods according to embodiments of the invention. Methods and compositions according to embodiments of the invention find use in a variety of different applications, including but not limited to, the treatment of bone adsorption disease conditions.

Abstract: Organoleptically acceptable solid oral dosage formulations of ibuprofen, and methods of making and using the same, are provided. A feature of the subject formulations is that they include ibuprofen and a masking component. In certain embodiments, the masking component includes one or more of a cooling agent, an organic acid and a cyclodextrin. The subject invention finds use in a variety of applications.

Abstract: Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.

Abstract: Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.

Abstract: A physiologically active substance well capable of permeating biomembrane according to the present invention is represented by: ##STR1## where R represents a residue of a physiologically active substance comprising a peptide, amino acid, aliphatic amine having a phenol skeleton, amino sugar, nucleoside or lactam compound and a residue of physiologically active derivative thereof. The biomembrane permeability of a substance with poor biomembrane permeability can be improved by introducing an adamantyl group to the physiologically active substance.

Abstract: A high-absorbable transvaginal preparation having excellent absorbability of the active ingredient, which comprises a biologically active polypeptide and an absorption promoter comprising a polyoxyethylenealkylphenyl ether and one or more compounds selected from the group consisting of an N-acylamino acid, cholic acids, pectic acid, taurine, saccharin, glycyrrhizic acid, aspartame, or a salt thereof.

Abstract: Thiophene derivatives of the formula ##STR1## wherein X, Y and Z are as herein defined, said compounds being useful as fungicides, are described.